Mitochondria-Derived Peptide Treats Painful Diabetic Neuropathy by Boosting Mitochondrial Biogenesis

Painful diabetic neuropathy (PDN) is a debilitating complication of diabetes, characterized by chronic nerve pain and often associated with mitochondrial dysfunction in nerve cells. Current treatments for PDN primarily manage symptoms and often have limited efficacy, highlighting the urgent need for novel therapeutic strategies that address the underlying pathology. This study investigates whether a mitochondria-derived peptide (MDP) can effectively treat PDN by enhancing mitochondrial health and function.

Treatment with MDP significantly alleviated pain behaviors in diabetic rats. Mechanical allodynia, a measure of pain sensitivity, was reduced by 55% (p<0.001) in the MDP-treated group compared to untreated diabetic controls. Thermal hyperalgesia also showed a significant improvement, with withdrawal latencies increasing by 40% (p<0.01). The most significant finding was that MDP robustly induced mitochondrial biogenesis, evidenced by a 2.5-fold increase in PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) expression and a 2-fold increase in TFAM (mitochondrial transcription factor A) levels in nerve tissues (p<0.001 for both). This was accompanied by a 30% increase in ATP production and a 25% reduction in reactive oxygen species (ROS) compared to diabetic controls (p<0.05).